Global Cancer Diagnostics Market Research Report 2019

2 Global Cancer Diagnostics Quarterly Market Size Analysis

• 2.1 Cancer Diagnostics Business Impact Assessment - COVID-19
  • 2.1.1 Global Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cancer Diagnostics Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cancer Diagnostics Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cancer Diagnostics Market
• 3.4 Key Players Cancer Diagnostics Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cancer Diagnostics Segments, By Type

• 4.1 Introduction
  • 1.4.1 Platform-based
  • 1.4.2 Instrument-based
• 4.2 By Type, Global Cancer Diagnostics Market Size, 2019-2021

5 Impact of Covid-19 on Cancer Diagnostics Segments, By Application

• 5.1 Overview
  • 5.5.1 Breast Cancer
  • 5.5.2 Lung Cancer
  • 5.5.3 Colorectal Cancer
  • 5.5.4 Melanoma
  • 5.5.5 Others
• 5.2 By Application, Global Cancer Diagnostics Market Size, 2019-2021
  • 5.2.1 By Application, Global Cancer Diagnostics Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Becton, Dickinson and Company
  • 7.1.1 Becton, Dickinson and Company Business Overview
  • 7.1.2 Becton, Dickinson and Company Cancer Diagnostics Quarterly Revenue, 2020
  • 7.1.3 Becton, Dickinson and Company Cancer Diagnostics Product Introduction
  • 7.1.4 Becton, Dickinson and Company Response to COVID-19 and Related Developments
• 7.2 GE Healthcare
  • 7.2.1 GE Healthcare Business Overview
  • 7.2.2 GE Healthcare Cancer Diagnostics Quarterly Revenue, 2020
  • 7.2.3 GE Healthcare Cancer Diagnostics Product Introduction
  • 7.2.4 GE Healthcare Response to COVID-19 and Related Developments
• 7.3 Abbott
  • 7.3.1 Abbott Business Overview
  • 7.3.2 Abbott Cancer Diagnostics Quarterly Revenue, 2020
  • 7.3.3 Abbott Cancer Diagnostics Product Introduction
  • 7.3.4 Abbott Response to COVID-19 and Related Developments
• 7.4 Roche
  • 7.4.1 Roche Business Overview
  • 7.4.2 Roche Cancer Diagnostics Quarterly Revenue, 2020
  • 7.4.3 Roche Cancer Diagnostics Product Introduction
  • 7.4.4 Roche Response to COVID-19 and Related Developments
• 7.5 Thermo Fisher Scientific
  • 7.5.1 Thermo Fisher Scientific Business Overview
  • 7.5.2 Thermo Fisher Scientific Cancer Diagnostics Quarterly Revenue, 2020
  • 7.5.3 Thermo Fisher Scientific Cancer Diagnostics Product Introduction
  • 7.5.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
• 7.6 Agilent Technologies
  • 7.6.1 Agilent Technologies Business Overview
  • 7.6.2 Agilent Technologies Cancer Diagnostics Quarterly Revenue, 2020
  • 7.6.3 Agilent Technologies Cancer Diagnostics Product Introduction
  • 7.6.4 Agilent Technologies Response to COVID-19 and Related Developments
• 7.7 Illumina
  • 7.7.1 Illumina Business Overview
  • 7.7.2 Illumina Cancer Diagnostics Quarterly Revenue, 2020
  • 7.7.3 Illumina Cancer Diagnostics Product Introduction
  • 7.7.4 Illumina Response to COVID-19 and Related Developments
• 7.8 Siemens Healthcare
  • 7.8.1 Siemens Healthcare Business Overview
  • 7.8.2 Siemens Healthcare Cancer Diagnostics Quarterly Revenue, 2020
  • 7.8.3 Siemens Healthcare Cancer Diagnostics Product Introduction
  • 7.8.4 Siemens Healthcare Response to COVID-19 and Related Developments
• 7.9 C.R. Bard
  • 7.9.1 C.R. Bard Business Overview
  • 7.9.2 C.R. Bard Cancer Diagnostics Quarterly Revenue, 2020
  • 7.9.3 C.R. Bard Cancer Diagnostics Product Introduction
  • 7.9.4 C.R. Bard Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US